Gout drug could offer hope for heart failure patients

November 12, 2001

A medication commonly used for gout holds possibilities for the treatment of heart failure, Johns Hopkins researchers report. It's a drug that works by a new principle, namely, directly decreasing heart muscle's need for energy and making it contract more efficiently.

When allopurinol was injected into the hearts of nine patients with congestive heart failure, it significantly improved the organs' efficiency. Results are reported in the Nov. 13 issue of Circulation, an American Heart Association journal.

Heart failure can be compared to a car that's out of tune. The heart still functions, but it's not efficient. As the heart worsens, it must work harder, requiring stepped-up, energy-producing reactions that enable it to contract and pump blood. In the Hopkins study, allopurinol improved overall heart efficiency. The hearts of patients treated with the medication had a 20 percent reduction in energy consumption with no reduction in contraction strength.

"Allopurinol represents a novel potential strategy for the treatment of heart failure," says Joshua M. Hare, M.D., senior author of the study and director of Hopkins' heart failure research program. "It allowed the heart to use less oxygen without any detrimental effects on its function."

For the study, Hare and colleagues looked at nine patients (seven men and two women) with dilated cardiomyopathy - a cause of severe heart failure in which the lower left chamber of the heart becomes enlarged and weakened. Patients were taking standard medications for congestive heart failure, including ACE inhibitors and beta blockers.

Allopurinol was infused directly into the heart while researchers recorded the patients' heart performance. The research team also took tissue samples from cardiomyopathy patients undergoing heart transplant and used them to measure amounts of xanthine oxidase (XO) - an enzyme involved in normal tissue metabolism.

XO contributes to the heart's demise in ways not yet understood. The researchers found that amounts of XO were significantly higher in heart failure patients.

Researchers believe that when XO goes awry, it releases free radicals that disrupt the body's energy-producing machinery. Allopurinol works by inhibiting this. In gout, the drug blocks uric acid crystals from building up in the joints and causing inflammation, swelling and pain.

Hare plans to start clinical trials of allopurinol for heart failure within the next year. The study was supported in part by the National Institutes of Health. Other authors were Thomas P. Cappola, M.D.; David A. Kass, M.D.; Gregory S. Nelson, Ph.D.; Ronald D. Berger, M.D., Ph.D.; Gisele O. Rosas, Ph.D.; Zoulficar A. Kobeissi, M.D.; and Eduardo Marbán, M.D.

Marbán holds equity in Paralex Inc., a company that seeks to investigate the therapeutic potential of xanthine oxidase inhibitors for various indications. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. The present study was completed before Paralex was incorporated, and no financial support was received from Paralex.
-end-
Cappola, T.P., et. al., "Allopurinol Improves Myocardial Efficiency in Patients with Idiopathic Dilated Cardiomyopathy," Circulation, Nov. 13, 2001, Vol. 104.

Related Web sites:

Johns Hopkins Cardiomyopathy and Heart Transplant Service
http://www.med.jhu.edu/heart.

American Heart Association
http://www.americanheart.org

Media contact: Karen Blum 410-955-1534, Email: kblum@jhmi.edu

Johns Hopkins Medical Institutions' news releases are available on an EMBARGOED basis on EurekAlert at http://www.eurekalert.org Newswise at http://www.newswise.com and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkins@jhmi.edu

On a POST-EMBARGOED basis find them at http://www.hopkinsmedicine.org and Quadnet at http://www.quad-net.com

Johns Hopkins Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.